Acute and Long-Term Suppression of Stress-Induced ACTH Secretion by a Rat Monoclonal Antibody to Corticotropin Releasing Factor

1989 ◽  
pp. 287-292 ◽  
Author(s):  
J. W. A. M. Van Oers ◽  
F. J. H. Tilders ◽  
F. Berkenbosch
Keyword(s):  
Monoclonal Antibody ◽  
Corticotropin Releasing Factor ◽  
Acth Secretion

Long-term effects of hypothalamic paraventricular lesion on CRF content and stimulated ACTH secretion

1986 ◽  
Vol 250 (3) ◽  
pp. E319-E324 ◽  
Author(s):  
G. B. Makara ◽  
E. Stark ◽  
G. Kapocs ◽  
F. A. Antoni
Keyword(s):  
Corticotropin Releasing Factor ◽  
Long Term Effects ◽  
Plasma Acth ◽  
Acth Secretion ◽  
Short Term ◽  
Neural Lobe ◽  
Ether Anesthesia ◽  
Acth Release

The effect of short-term (1 wk) and long-term (6 wk) lesion of the paraventricular nucleus (PVN) on the hypothalamopituitary-adrenal axis was studied. Six weeks after PVN lesion there was no change in resting morning plasma ACTH and corticosterone levels. The increase of plasma ACTH levels that occurs 8 days after adrenalectomy was inhibited 6 wk after placing a lesion in the PVN. In contrast, 6 wk after PVN lesion the plasma ACTH response measured 3 min after laparatomy and intestinal traction under ether anesthesia was not significantly different from that in the controls. The responsiveness to corticotropin-releasing factor (CRF)-41 of anterior pituitary segments incubated in vitro increased slightly at 6 wk after PVN lesion. The amount of CRF-41-like immunoreactive material in the stalk-median eminence decreased to approximately 14% of the control, while that in neural lobe failed to change. We suggest that the ACTH hypersecretion after adrenalectomy is driven predominantly by CRF-and/or AVP-producing neurons in and around the PVN, whereas other sources of CRF-41, increased pituitary sensitivity or other hypothalamic factors, may restore stress-induced ACTH release in the absence of the region of the PVN.

scholarly journals Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity

2014 ◽  
Vol 3 (9) ◽  
pp. e955684 ◽  
Author(s):  
Henri-Alexandre Michaud ◽  
Jean-François Eliaou ◽  
Virginie Lafont ◽  
Nathalie Bonnefoy ◽  
Laurent Gros
Keyword(s):  
Monoclonal Antibody ◽  
Tumor Antigen ◽  
Antitumor Immunity

539 LONG-TERM TREATMENT OF PATIENTS WITH EOSINOPHILIC GASTRITIS AND/OR EOSINOPHILIC DUODENITIS WITH LIRENTELIMAB, A MONOCLONAL ANTIBODY AGAINST SIGLEC-8

2021 ◽  
Vol 160 (6) ◽  
pp. S-111
Author(s):  
Kathryn A. Peterson ◽  
Mirna Chehade ◽  
Joseph A. Murray ◽  
Gary W. Falk ◽  
Nirmala Gonsalves ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Term Treatment ◽  
Eosinophilic Gastritis ◽  
Long Term Treatment

scholarly journals Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial

2014 ◽  
Vol 168 (5) ◽  
pp. 682-689.e1 ◽  
Author(s):  
Gregory G. Schwartz ◽  
Laurence Bessac ◽  
Lisa G. Berdan ◽  
Deepak L. Bhatt ◽  
Vera Bittner ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Acute Coronary Syndromes ◽  
Cardiovascular Outcomes ◽  
Coronary Syndromes
Sign in / Sign up

Export Citation Format

Share Document